Patents by Inventor David W. Silversides

David W. Silversides has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5596089
    Abstract: The present invention relates to novel bovine (SEQ ID NO:1) and porcine (SEQ ID NO:2) genomic sequences for the SRY gene along with oligonucleotide primers. The present invention also relates to a method of sexing bovine or porcine tissue by descriminating PCR products obtained by amplification of specific DNA or cDNA sequences of bovine or porcine tissue which is used as a DNA template and wherein two pairs of DNA primers are used for the PCR. The present invention also relates to a method for the genetic manipulation or selection of sexual phenotype in domesticated animals, which comprises using transgenes composed of SRY sequences to cause and control the expression of genetic ablation sequences and genetic switching sequences in undifferentiated and developing gonadal tissues of both XX and XY animals.
    Type: Grant
    Filed: February 14, 1994
    Date of Patent: January 21, 1997
    Assignee: Universite De Montreal
    Inventors: David W. Silversides, Isabelle M. Daneau, Alain Houde
  • Patent number: 4975420
    Abstract: A technique has been developed to cause a mammal to generate antibodies which will bind to its native GnRH thus suppressing the mammal's fertility. The technique involves vaccinating a mammal with a novel conjugate of an immuno stimulating carrier and a novel GnRH analogue. The analogue is substantially identical to the natural GnRH which is common to all mammals except that one or more of the normally occurring amino acids of this decapeptide have been replaced by an amino acid with a more reactive side group. A favored technique is to utilize an analogue containing cysteine which, of course, has as a sulfhydryl side group. This analogue may then be conjugated to a large protein carrier using a heterobifunctional agent carrying a group reactive with carboxyl or amino groups and a group reactive with sulfhydryl groups. This conjugate then forms the immunogen base for a vaccine which may also contain art recognized adjuvants.
    Type: Grant
    Filed: September 30, 1987
    Date of Patent: December 4, 1990
    Assignee: University of Saskatchewan
    Inventors: David W. Silversides, Bruce D. Murphy, Reuben J. Mapletoft, Vikram Misra, Anne F. Allen
  • Patent number: 4879112
    Abstract: A monoclonal antibody against GnRH and particularly designated USASK/DSIL-GnRH is produced by a hybrid formed by fusion of cells from a myeloma line and antibody producing cells of the immune system from an animal previously immunized with a source of GnRH; the monoclonal antibody has the following characteristics:(i) it produces a short term reduced mean level of luteinizing hormone (LH) in immunized mammals;(ii) it produces a short term reduced pulsatile secretion of LH in immunized mammals;(iii) it terminates pregnancy in a female mammal with an accompanying decline in progesterone levels;(iv) it produces a long term reduced testosterone level in a male mammal, and,(v) it induces inferility in a male mammal;thus passive immunization of the female or male with the monoclonal antibodies may be employed to reduce fertility and terminate pregnancy.
    Type: Grant
    Filed: May 15, 1987
    Date of Patent: November 7, 1989
    Assignee: University of Saskatchewan
    Inventors: David W. Silversides, Reuben J. Mapletoft, Bruce D. Murphy, Virkam Misra
  • Patent number: 4676981
    Abstract: A monoclonal antibody against GnRH and particularly designated USASK/DSIL-GnRH is produced by a hybrid formed by fusion of cells from a myeloma line and antibody producing cells of the immune system from an animal previously immunized with a source of GnRH; the monoclonal antibody has the following characteristics:(i) it produces a short term reduced means level of luteinizing hormone (LH) in immunized mammals;(ii) it produces a short term reduced pulsatile secretion of LH in immunized mammals;(iii) it terminates pregnancy in a female mammal with an accompanying decline in progesterone levels;(iv) it produces a long term reduced testosterone level in a male mammal, and(v) it induces infertility in a male mammal; thus passive immunization of the female or male with the monoclonal antibodies may be employed to reduce fertility and terminate pregnancy.
    Type: Grant
    Filed: February 7, 1984
    Date of Patent: June 30, 1987
    Assignee: University of Saskatchewan
    Inventors: David W. Silversides, Reuben J. Mapletoft, Bruce D. Murphy, Vikram Misra